CTMXCytomX Therapeutics, Inc.

CTMX Stock Price, Valuation & Chart | CytomX Therapeutics, Inc.

Compare

$3.670+0.31 (+9.23%)

At close · 01 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology CTMX intrinsic value CTMX calculated fair value vs price

Overview Financials Dividends Ratios

CTMX Historical price chart

CTMX Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization798.97M

PE Ratio-8.93

EPS-0.41

Trading Volume8.82M

Today's High/Low3.73/3.32

Dividend Yield0.00

52 Week High/Low8.21/1.9

Shares Outstanding217.70M

CTMX Financial Statement

CTMX Analyst ratings

CTMX Analysis & performance metrics

CTMX Company profile

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody…

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast…

CTMX Management team

Name

Position

Lloyd A. Rowland Jr., J.D.

Senior Vice President, General Counsel, Chief Compliance Officer & Secretary

Leslie Robbins

Senior Vice President of Intellectual Property

Dawn Benson

Senior Vice President of Quality & Product Manufacturing

Stephanie Robertson Ph.D.

Senior Vice President of Alliances & Program Leadership

Danielle Olander-Moghadassian

Senior Vice President & Chief Human Resources Officer

Sean A. McCarthy DPHILCEO

Chairman & Chief Executive Officer

Hoyoung Huh M.D., Ph.D.CEO

Special Advisor to Chief Executive Officer

Christopher W. OgdenCFO

SVice President & Chief Financial Officer

Name

Position

Lloyd A. Rowland Jr., J.D.

Senior Vice President, General Counsel, Chief Compliance Officer & Secretary

Leslie Robbins

Senior Vice President of Intellectual Property

Dawn Benson

Senior Vice President of Quality & Product Manufacturing

Stephanie Robertson Ph.D.

Senior Vice President of Alliances & Program Leadership

Danielle Olander-Moghadassian

Senior Vice President & Chief Human Resources Officer

Sean A. McCarthy DPHILCEO

Chairman & Chief Executive Officer

Hoyoung Huh M.D., Ph.D.CEO

Special Advisor to Chief Executive Officer

Christopher W. OgdenCFO

SVice President & Chief Financial Officer

Management Team

Lloyd A. Rowland Jr., J.D.

Senior Vice President, General Counsel, Chief Compliance Officer & Secretary

Leslie Robbins

Senior Vice President of Intellectual Property

Dawn Benson

Senior Vice President of Quality & Product Manufacturing

Stephanie Robertson Ph.D.

Senior Vice President of Alliances & Program Leadership

Danielle Olander-Moghadassian

Senior Vice President & Chief Human Resources Officer

Sean A. McCarthy DPHILCEO

Chairman & Chief Executive Officer

Hoyoung Huh M.D., Ph.D.CEO

Special Advisor to Chief Executive Officer

Christopher W. OgdenCFO

SVice President & Chief Financial Officer

Management

Lloyd A. Rowland Jr., J.D.

Senior Vice President, General Counsel, Chief Compliance Officer & Secretary

Leslie Robbins

Senior Vice President of Intellectual Property

Dawn Benson

Senior Vice President of Quality & Product Manufacturing

Stephanie Robertson Ph.D.

Senior Vice President of Alliances & Program Leadership

Danielle Olander-Moghadassian

Senior Vice President & Chief Human Resources Officer

Sean A. McCarthy DPHILCEO

Chairman & Chief Executive Officer

Hoyoung Huh M.D., Ph.D.CEO

Special Advisor to Chief Executive Officer

Christopher W. OgdenCFO

SVice President & Chief Financial Officer

Total 8 executives

CTMX Frequently asked questions

What is CytomX Therapeutics, Inc. (CTMX) Stock Price?

Current stock price of CytomX Therapeutics, Inc. (CTMX) stock is $3.670. The stock price is +9.23% higher in the session. The intraday range can be seen from this page. Volume of CytomX Therapeutics, Inc. (CTMX) stock is 8.82M.

Last updated at 01 Sept 2026, 08:00 pm.

Why is the CytomX Therapeutics, Inc. (CTMX) stock price going up or down today?

The stock price of CytomX Therapeutics, Inc. (CTMX) can change with earnings, company news, and overall market sentiment. CytomX Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the CytomX Therapeutics, Inc. stock expensive at its current price?

Whether CytomX Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for CTMX on this page is -8.93. EPS on this page is -0.41. Compare those figures with peers and growth expectations before deciding if the current CytomX Therapeutics, Inc. price is justified.

How has the stock price of CytomX Therapeutics, Inc. (CTMX) performed historically?

Historical performance for CytomX Therapeutics, Inc. (CTMX) is shown on the price chart on this page. Review multi-period moves alongside volume to see how CTMX reacted to past earnings and market events.

Should I buy CytomX Therapeutics, Inc. (CTMX) stock, at this price?

Buying CytomX Therapeutics, Inc. (CTMX) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.